An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

About the trial

Sponsor

Emory University (with National Cancer Institute (NCI), National Institutes of Health (NIH))

Tested

Flotufolastat F-18 Gallium (drug), Magnetic Resonance Imaging (procedure), Multiparametric Magnetic Resonance Imaging (procedure), Positron Emission Tomography (procedure), Transrectal Ultrasonography Guided Biopsy (procedure)

Dates

Started 2025-04-18; completion 2029-12-31

Results posted

Not yet

This phase II trial evaluates an imaging technique called 18F-rhPSMA-7.3 positron emission tomography (PET)-multiparametric (mp) magnetic resonance imaging (MRI) in identifying tumor tissue in men suspected to have prostate cancer. This clinical trial also seeks to determine if the abnormal tissue identified during imaging represents the tumor tissue removed during transrectal ultrasound-magnetic resonance imaging (TRUS-MR) fusion biopsy of the prostate. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 18F-rhPSMA-7.3. Because some tumors take up 18F-rhPSMA-7.3 it can be seen with …

From ClinicalTrials.gov, last updated 2026-07-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Blue Earth Diagnostics reported $25,329 in research payments for this study in 2025 (5 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.